<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE us-patent-application SYSTEM "us-patent-application-v43-2012-12-04.dtd" [ ]><us-patent-application lang="EN" dtd-version="v4.3 2012-12-04" file="US20140005184A1-20140102.XML" status="PRODUCTION" id="us-patent-application" country="US" date-produced="20131218" date-publ="20140102"><us-bibliographic-data-application lang="EN" country="US"><publication-reference><document-id><country>US</country><doc-number>20140005184</doc-number><kind>A1</kind><date>20140102</date></document-id></publication-reference><application-reference appl-type="utility"><document-id><country>US</country><doc-number>13902589</doc-number><date>20130524</date></document-id></application-reference><us-application-series-code>13</us-application-series-code><classifications-ipcr><classification-ipcr><ipc-version-indicator><date>20060101</date></ipc-version-indicator><classification-level>A</classification-level><section>C</section><class>07</class><subclass>D</subclass><main-group>498</main-group><subgroup>06</subgroup><symbol-position>F</symbol-position><classification-value>I</classification-value><action-date><date>20140102</date></action-date><generating-office><country>US</country></generating-office><classification-status>B</classification-status><classification-data-source>H</classification-data-source></classification-ipcr><classification-ipcr><ipc-version-indicator><date>20060101</date></ipc-version-indicator><classification-level>A</classification-level><section>A</section><class>61</class><subclass>J</subclass><main-group>1</main-group><subgroup>00</subgroup><symbol-position>L</symbol-position><classification-value>I</classification-value><action-date><date>20140102</date></action-date><generating-office><country>US</country></generating-office><classification-status>B</classification-status><classification-data-source>H</classification-data-source></classification-ipcr><classification-ipcr><ipc-version-indicator><date>20060101</date></ipc-version-indicator><classification-level>A</classification-level><section>C</section><class>07</class><subclass>D</subclass><main-group>498</main-group><subgroup>20</subgroup><symbol-position>L</symbol-position><classification-value>I</classification-value><action-date><date>20140102</date></action-date><generating-office><country>US</country></generating-office><classification-status>B</classification-status><classification-data-source>H</classification-data-source></classification-ipcr></classifications-ipcr><classifications-cpc><main-cpc><classification-cpc><cpc-version-indicator><date>20130101</date></cpc-version-indicator><section>C</section><class>07</class><subclass>D</subclass><main-group>498</main-group><subgroup>06</subgroup><symbol-position>F</symbol-position><classification-value>I</classification-value><action-date><date>20140102</date></action-date><generating-office><country>US</country></generating-office><classification-status>B</classification-status><classification-data-source>H</classification-data-source><scheme-origination-code>C</scheme-origination-code></classification-cpc></main-cpc><further-cpc><classification-cpc><cpc-version-indicator><date>20130101</date></cpc-version-indicator><section>C</section><class>07</class><subclass>D</subclass><main-group>498</main-group><subgroup>20</subgroup><symbol-position>L</symbol-position><classification-value>I</classification-value><action-date><date>20140102</date></action-date><generating-office><country>US</country></generating-office><classification-status>B</classification-status><classification-data-source>H</classification-data-source><scheme-origination-code>C</scheme-origination-code></classification-cpc><classification-cpc><cpc-version-indicator><date>20130101</date></cpc-version-indicator><section>A</section><class>61</class><subclass>J</subclass><main-group>1</main-group><subgroup>00</subgroup><symbol-position>L</symbol-position><classification-value>I</classification-value><action-date><date>20140102</date></action-date><generating-office><country>US</country></generating-office><classification-status>B</classification-status><classification-data-source>H</classification-data-source><scheme-origination-code>C</scheme-origination-code></classification-cpc></further-cpc></classifications-cpc><classification-national><country>US</country><main-classification>5142302</main-classification><further-classification>544 71</further-classification><further-classification>540543</further-classification><further-classification>2064595</further-classification></classification-national><invention-title id="d0e43">SPIROCYCLIC AMINOQUINOLONES AS GSK-3 INHIBITORS</invention-title><us-related-documents><continuation><relation><parent-doc><document-id><country>US</country><doc-number>12678120</doc-number><date>20100824</date></document-id><parent-grant-document><document-id><country>US</country><doc-number>8476261</doc-number></document-id></parent-grant-document><parent-pct-document><document-id><country>WO</country><doc-number>PCT/US08/10700</doc-number><date>20080912</date></document-id></parent-pct-document></parent-doc><child-doc><document-id><country>US</country><doc-number>13902589</doc-number></document-id></child-doc></relation></continuation><us-provisional-application><document-id><country>US</country><doc-number>60993545</doc-number><date>20070912</date></document-id></us-provisional-application></us-related-documents><us-parties><us-applicants><us-applicant sequence="00" app-type="applicant" designation="us-only" applicant-authority-category="assignee"><addressbook><orgname>KYORIN PHARMACEUTICALS CO., LTD.</orgname><address><city>Chiyoda-ku</city><country>JP</country></address></addressbook><residence><country>JP</country></residence></us-applicant></us-applicants><inventors><inventor sequence="00" designation="us-only"><addressbook><last-name>COCIORVA</last-name><first-name>Oana</first-name><address><city>San Diego</city><state>CA</state><country>US</country></address></addressbook></inventor><inventor sequence="01" designation="us-only"><addressbook><last-name>FUKUDA</last-name><first-name>Yasumichi</first-name><address><city>Shimotsuga-gun</city><country>JP</country></address></addressbook></inventor><inventor sequence="02" designation="us-only"><addressbook><last-name>KOHNO</last-name><first-name>Yasushi</first-name><address><city>Shimotsuga-gun</city><country>JP</country></address></addressbook></inventor><inventor sequence="03" designation="us-only"><addressbook><last-name>LI</last-name><first-name>Bei</first-name><address><city>San Diego</city><state>CA</state><country>US</country></address></addressbook></inventor><inventor sequence="04" designation="us-only"><addressbook><last-name>OKADA</last-name><first-name>Kyoko</first-name><address><city>Shimotsuga-gun</city><country>JP</country></address></addressbook></inventor><inventor sequence="05" designation="us-only"><addressbook><last-name>NAKAMURA</last-name><first-name>Ayako</first-name><address><city>Shimotsuga-gun</city><country>JP</country></address></addressbook></inventor><inventor sequence="06" designation="us-only"><addressbook><last-name>NOMURA</last-name><first-name>Masahiro</first-name><address><city>Shimotsuga-gun</city><country>JP</country></address></addressbook></inventor><inventor sequence="07" designation="us-only"><addressbook><last-name>SETO</last-name><first-name>Shigeki</first-name><address><city>Shimotsuga-gun</city><country>JP</country></address></addressbook></inventor><inventor sequence="08" designation="us-only"><addressbook><last-name>SZARDENINGS</last-name><first-name>Anna Katrin</first-name><address><city>Torrance</city><state>CA</state><country>US</country></address></addressbook></inventor><inventor sequence="09" designation="us-only"><addressbook><last-name>YUMOTO</last-name><first-name>Kazuhiro</first-name><address><city>Shimotsuga-gun</city><country>JP</country></address></addressbook></inventor></inventors></us-parties><assignees><assignee><addressbook><orgname>KYORIN PHARMACEUTICALS CO., LTD.</orgname><role>03</role><address><city>Chiyoda-ku</city><country>JP</country></address></addressbook></assignee></assignees></us-bibliographic-data-application><abstract id="abstract"><p id="p-0001" num="0000">Provided herein are spirocyclic aminoquinolones of formula I and compositions containing the compounds. The compounds and compositions provided herein are useful in the prevention, amelioration or treatment of GSK-3 inhibitors mediated diseases.</p></abstract></us-patent-application>